Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 38Paclitaxel 22Epirubicin 21Trastuzumab 20Docetaxel 20Doxorubicin 19Carboplatin 15Radiotherapy 13Taxes 11Filgrastim 11Neoadjuvant Therapy 9Bevacizumab 9Fluorouracil 8pembrolizumab 7Tamoxifen 7Albumin-Bound Paclitaxel 7Capecitabine 6pertuzumab 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Lapatinib 5130-nm albumin-bound paclitaxel 5pegfilgrastim 4Granulocyte Colony-Stimulating Factor 4Cisplatin 4Chemotherapy, Adjuvant 4Biopsy 4tipifarnib 3eribulin 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inflammatory Breast Neoplasms × onvansertib × Clear all
NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡